Prosecution Insights
Last updated: November 12, 2026
Application No. 18/716,935

AFFINITY PURIFICATION, PROXIMITY-BASED SORTASE LIGATION, AND DETECTION OF PROTEINS WITH PRECURSOR PEPTIDES AND B1 PROTEINS FROM LASSO PEPTIDE BIOSYNTHESIS SYSTEMS

Non-Final OA §112
Filed
Jun 06, 2024
Priority
Dec 10, 2021 — provisional 63/288,483 +2 more
Examiner
UNDERDAHL, THANE E
Art Unit
1699
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Alphathera LLC
OA Round
1 (Non-Final)
59%
Grant Probability
Moderate
1-2
OA Rounds
99%
With Interview

Examiner Intelligence

Grants 59% of resolved cases
59%
Career Allowance Rate
326 granted / 554 resolved
-1.2% vs TC avg
Strong +50% interview lift
Without
With
+50.1%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
34 currently pending
Career history
600
Total Applications
across all art units

Office Action

§112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Detailed Action This Office Action is in response to the Applicant’s reply received 8/5/26. Claims 1, 5, 7-9, 11, 12, 17, 20-23, 25-29, 31-32, 36, 40, 41, 44, 45, 51, 54-58, 60, and 66 are pending. Claims 8, 22, 23, 25-29, 31-32, 36, 40, 41, 44, 45, 51, 54-58, 60, and 66 are withdrawn. Claims 1, 5, 7-9, 11, 12, 17, 20, and 21 are considered on the merits. Election/Restriction Requirement Applicant’s election of Group I, claims 1-3 and 5-10, without traverse in the reply filed on 8/5/26 is acknowledged. Applicant elected the following species: For leader peptide and B1 protein: leader peptide TfuA and B1 protein TfuB1 from Thermobifida fusca; For affinity tag: histidine tag (His tag); For structure of the conjugate protein: the first fusion protein has a second affinity tag having a selective affinity for a second affinity tag resin; For Sortase: sortase A (SrtA); and For sortase recognition motif: LPXTG (SEQ ID NO: 1); As a result of these elections, claim 8 is withdrawn as the non-elected species from iii). In summary claims 8, 22, 23, 25-29, 31-32, 36, 40, 41, 44, 45, 51, 54-58, 60, and 66 are withdrawn as a result of this Election/Restriction requirement. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1, 5, 7-9, 11, 12, 17, 20, and 21 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. The complete structure of this conjugated protein is indefinite for the following reasons: The phrases “[component] is N-terminal and connected via a linker” is confusing because it does not clearly indicate how the components (protein of interest, sortase recognition motif, and binding pair member) are arranged. All proteins have an N-terminus. It is unclear what is connected to the N-terminal of each component of these fusion proteins. Applicant may wish to amend to “the protein of interest is connected via a linker to the N-terminus of the sortase recognition motif”. This provides a clear description of how the components are linked together. This also applies to other situations where “N-terminal and connected via a linker” appears in the claims including both (i) and (ii) of claim 1; The final phrase “wherein the binding pair members comprise one or more leader peptides in tandem and one or more B1 proteins in tandem from a lasso peptide biosynthesis system that can form a heterodimer.” is unclear because “can form a heterodimer” leaves the final structure as optional and therefore undefined. Also ‘tandem’ is a relative term. In this case it is unclear what is ‘in tandem’ with the leader peptides or the one or more B1 proteins. Also it is unclear how the leader peptides are integrated into the lasso peptide biosynthesis to elucidate a final structure of the claims; And The claim does not clearly identify how the 1st and 2nd fusion proteins are conjugated as limited in the preamble. It is presumed from the diagrams that both binding pair members link to for a heterodimer, but this structure is not clearly stated in the claims. Closest Prior Art Because of the significant 35 USC 112 issues above, it is difficult to clearly apply prior art to these claims. However, based on a comparison of the figures, it appears the closest prior art is WO2018/053180 (in IDS 3/9/26, also published as US 11236177). Current Fig. 1 and Fig 2 of WO’180 appear to disclose similar structures. Request for Interview The Examiner believes an interview would be useful in progressing this case to resolve the 35 USC 112 issues already listed. The Applicant is encouraged to contact Thane Underdahl at (303) 297-4299 to discuss the claims/claim amendments to place this case in condition for allowance prior to replying to this Office Action. In response to this office action the applicant should specifically point out the support for any amendments made to the disclosure, including the claims (MPEP 714.02 and 2163.06). CONTACT INFORMATION Any inquiry concerning this communication or earlier communications from the examiner should be directed to THANE E UNDERDAHL whose telephone number is (303) 297-4299. The examiner can normally be reached Monday through Thursday, M-F 8-5 MST. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Fereydoun Sajjadi can be reached at (571) 272-3311.The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /THANE UNDERDAHL/Primary Examiner, Art Unit 1699
Read full office action

Prosecution Timeline

Jun 06, 2024
Application Filed
Oct 20, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12790597
BIOLOGICAL DEVICES FOR THE DETECTION AND CATABOLISM OF ALCOHOL AND OPIOIDS AND METHODS OF USE THEREOF
1y 10m to grant Granted Nov 10, 2026
Patent 12760127
An Auricularia Auricula Polysaccharide, Its Application And Preparation Method Thereof
3y 9m to grant Granted Oct 13, 2026
Patent 12760099
MULTIPARTITE SIGNALING PROTEINS AND USES THEREOF
3y 11m to grant Granted Oct 13, 2026
Patent 12757903
BIOLOGICAL SEED-COATING AGENT (SCA) INCLUDING FERMENTATION BROTH OBTAINED BASED ON CO-CULTIVATION OF TRICHODERMA AND BACILLUS SEQUENTIALLY INOCULATED, AND PREPARATION METHOD THEREOF
3y 3m to grant Granted Oct 13, 2026
Patent 12729392
BIOMARKER COMPOSITION FOR PREDICTING PROGNOSIS OF BRAIN DISEASE CAUSED BY MICROPLASTIC EXPOSURE AND METHOD FOR PREDICTING PROGNOSIS USING SAME
3y 9m to grant Granted Sep 08, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
59%
Grant Probability
99%
With Interview (+50.1%)
Low
PTA Risk
Based on 554 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month